Scott Lunin
Scott Lunin
Partner
Share and Download Scott's Biography
- Share This Page
Download
Scott Lunin is a partner in the Corporate Practice Group who represents domestic and international companies in a wide range of capital markets, securities, public company reporting, and disclosure and corporate governance matters, with a particular emphasis on the life sciences and technology industries. Scott also frequently represents investment banks in capital markets transactions in the life sciences sector.
He has successfully represented clients in a wide range of complex capital markets transactions, including initial public offerings, follow-on equity offerings, PIPEs, at-the-market offerings, senior debt offerings and reverse merger transactions. He also counsels emerging companies on venture financings and readiness for the public markets.
Scott serves as principal outside counsel for a number of life sciences companies in which he provides strategic advice to boards of directors and management teams regarding significant transactions and public company obligations.
Before joining WilmerHale, Scott was a senior attorney at IBM, focusing on corporate and securities matters. He also practiced as a capital markets attorney at another global law firm. Earlier in his career, he served as an intelligence officer with the Defense Intelligence Agency.
Scott is a co-author of Initial Public Offerings: A Practical Guide to Going Public, a leading resource for companies and advisors navigating the IPO process. Scott also serves on the New York Board of Advisors for Life Science Cares, a national nonprofit organization that brings together companies in the life sciences industry to eliminate the impact of poverty.
Experience
-
INITIAL PUBLIC OFFERINGS:
- Schrödinger, a developer of a physics-based computational platform that enables discovery of novel molecules for drug development, in its $232 million initial public offering and subsequent public offerings
- Dyne Therapeutics, a clinical-stage neuromuscular disease company, in its $230 million initial public offering and in multiple subsequent public offerings
- Decibel Therapeutics, a clinical-stage biotechnology company, in its $127 million initial public offering
- Nabriva Therapeutics, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, in its $80 million initial public offering and in multiple subsequent public offerings
- Summit Therapeutics, a biopharmaceutical company, in its $34 million initial public offering and in subsequent capital raising transactions
- Underwriters in the $160 million initial public offering of Theseus Pharmaceuticals, a biopharmaceutical company focused on improving the lives of cancer patients
- Underwriters in the $75 million initial public offering of Entasis Therapeutics, developer of innovative product candidates to treat serious Gram-negative, multidrug-resistant bacterial infections
-
ADDITIONAL CAPITAL MARKETS:
- Climb Bio (f/k/a Eliem Therapeutics), a clinical-stage biotechnology company, in its $120 million private placement
- KALA BIO, a clinical-stage biopharmaceutical company, in multiple public and private offerings
- Underwriters in the $92 million follow-on offering of Candel Therapeutics, a clinical-stage biopharmaceutical company
- Underwriters in the $230 million follow-on offering of Celldex Therapeutics, a biopharmaceutical company
- Underwriters in the $126 million follow-on offering of MacroGenics, a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer
- Stealth Biotherapeutics, a biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, in a registered direct offering and concurrent private placement
- RA Capital in public and private investments in Belite Bio, C4 Therapeutics, Inhibrx Biosciences, Ovid Therapeutics, SAB Biotherapeutics, Taysha Gene Therapies and UroGen Pharma
- Casella Waste, a regional solid waste, recycling and resource management services company, in its $91 million follow-on offering
- Achillion Pharmaceuticals, a biopharmaceutical company, in its $50 million secondary offering
-
OTHER CORPORATE EXPERIENCE:
- Kalaris Therapeutics, a clinical-stage ophthalmology biotech company, in its reverse merger transaction with AlloVir, an allogeneic T cell immunotherapy company
- Climb Bio (f/k/a Eliem Therapeutics), a biotechnology company, in its acquisition of Tenet Medicines, a development-stage private biotechnology company focused on developing a potentially best-in class anti-CD19 antibody designed for a broad range of autoimmune diseases.
- Decibel Therapeutics, a clinical-stage biotechnology company, in its acquisition by Regeneron, a biopharmaceutical company
- Mural Oncology plc, a clinical-stage immuno-oncology company, in its acquisition by XOMA Royalty Corporation, a biotechnology royalty aggregator
- Summit Therapeutics, a biopharmaceutical company, in its redomiciliation from the United Kingdom to Delaware
Insights & News
Credentials
-
Education
-
JD, Georgetown University Law Center, 2009
cum laude Notes Editor, The Georgetown Law Journal -
BA, International Affairs, The George Washington University, 2003
magna cum laude Phi Beta Kappa
-
-
Admissions
-
New York
-
Credentials
-
Education
-
JD, Georgetown University Law Center, 2009
cum laude Notes Editor, The Georgetown Law Journal -
BA, International Affairs, The George Washington University, 2003
magna cum laude Phi Beta Kappa
-
-
Admissions
-
New York
-